This physiological diagram displays nine time-series graphs (A–I) illustrating intracellular calcium ([Ca2+]i) dynamics in adipocytes, measured via Fura-2 fluorescence ratios. The graphs demonstrate the synergistic and potentiation effects of various agonists on calcium signaling. Panels A and B show periodic, high-amplitude [Ca2+]i oscillations induced by the combination of Acetylcholine (ACh) and Norepinephrine (NE). Panel C depicts the inhibition of these oscillations using the M3-cholinergic receptor antagonist p-F-HHSID, resulting in only a single transient spike. Panels D–H illustrate diverse dynamic regimes triggered by ACh and the α1-adrenergic agonist Phenylephrine, including fast oscillations (D), impulse-shaped oscillations (E), relaxation-type oscillations (F), and transitions to new steady states (G, H). Panel I shows impulse-shaped oscillations elicited by the α2-adrenergic agonist UK-14,304 in the presence of ACh. The data illustrate complex nonlinear signaling pathways and the convergence of M3-cholinergic and α-adrenergic receptor activation in adipocyte calcium homeostasis.

A molecular pharmacology diagram illustrating the conformational switch of the Cannabinoid Receptor 2 (CB2R) between active (left) and inactive (right) states. The visual depicts a G protein-coupled receptor (GPCR) model featuring alpha-helical transmembrane domains. The central mechanism shown is the 'toggle switch' involving the Trp258 residue within a 'secondary site/toggle pocket'. On the left, the agonist HU-308 binds to the primary site, leaving Trp258 in an upright active conformation. On the right, a modified ligand stabilizes the inactive state through a stereogenic phenyl group that engages in an edge-to-face pi-interaction with Trp258, effectively 'switching off' receptor signaling. Key molecular modifications to the ligand for therapeutic development are highlighted: 1) fluorophore conjugation for imaging, 2) stereogenic phenyl group for functional inactivation (e.g., inhibiting beta-arrestin association and ERK1/2 phosphorylation), 3) azide incorporation for improved affinity, and 4) a novel resorcinol moiety. The diagram highlights structural biology concepts in drug design, specifically targeting the active/inactive equilibrium of GPCRs for pain modulation research.

This composite educational graphic illustrates the molecular pharmacology and structural biology of the Estrogen Receptor alpha (ERα) ligand-binding domain (LBD). Panel A presents surface-filling structural models of ERα bound to raloxifene, categorized by functional outcome. Antagonist configurations (D351, D351F, D351G) show the yellow-colored Helix 12 positioned to block coactivator binding. Agonist configurations (D351E, D351Y) demonstrate a conformational shift in Helix 12 and its proximity to the blue-colored protein surface, following mutations at the Asp351 residue (the anti-estrogenic region). Panel B provides detailed molecular modeling of the surface interaction between specific ligands and the D351/Y351 residue. It compares 4-hydroxytamoxifen (4-OHT) and raloxifene (Ral), highlighting the distance (3.8 Å) between the ligand alkylamine chain and the protein surface. Subpanel C shows how the Asp351Tyr mutation introduces steric considerations (Rotamer #2). Panel C displays the chemical structures of Raloxifene (featuring a piperidine ring) and its derivative R1h (featuring a cyclohexane ring), illustrating the importance of the nitrogen-containing side chain for anti-estrogenic activity.

This educational graphic presents Molecular Dynamics (MD) simulation data for Estrogen Receptor alpha (ERα) complexes bound with Resveratrol (RES) in both agonist and antagonist conformations. The image consists of four panels (A-D). Panels A and B are secondary structure profiles over a 10,000 ps simulation time for the agonist and antagonist complexes, respectively. The y-axis identifies residue numbers (0–240), with color-coding indicating structural elements: A-Helix (blue), Turn (yellow), B-Sheet (red), Coil (white), and Bend (green). Both profiles demonstrate high alpha-helical stability, particularly in the regions corresponding to the receptor's 12 helices. Panel C provides a line graph comparing the total number of structured residues for the agonist (black) and antagonist (red) complexes, fluctuating between approximately 170 and 200 residues. Panel D tracks the percentage of helical residues, showing both complexes maintain a high helical content between 70% and 85% throughout the simulation. This visual demonstrates the structural stability of ERα-LBD when bound to different ligand subtypes, relevant for pharmacology and structural biology studies on Selective Estrogen Receptor Modulators (SERMs).

This physiological data panel illustrates the noradrenergic modulation of respiratory rhythm in mouse brainstem slices, focusing on the pre-Bötzinger Complex (preBötC). Panels A and B display integrated population activity recordings (∫VRG) showing two distinct patterns: low-amplitude 'fictive eupneic' bursts and high-amplitude 'fictive sighs' (marked by asterisks). In Panel A, norepinephrine (NE, 20 μM) increases the frequency of both eupneic and sigh-like activity. Panel B demonstrates that the α1-adrenergic receptor antagonist prazosin (50 μM) selectively abolishes the NE-induced increase in eupneic frequency but fails to block the increase in sigh frequency, which remains elevated upon NE application. Panels C and D provide statistical histograms quantifying these effects, showing significant increases in sigh frequency and duration (expressed as percentage of control) following pharmacological intervention. The visual data supports the concept that sigh-like activity is modulated by noradrenergic pathways independent of α1-receptors, likely involving β-adrenergic mechanisms. This content is relevant for neurobiology and respiratory physiology, specifically studying central rhythmogenesis and autonomic control.

This pathophysiology diagram illustrates the multi-pathway signaling mechanisms by which physical activity inhibits cancer cell proliferation and influences tumor hallmarks. The central 'Physical Activity' node links to five distinct regulatory axes. 1) Adrenergic Signaling: Increased norepinephrine and epinephrine activate the Hippo Tumor Suppressor Pathway (MST 1/2 and LATS 1/2), leading to YAP/TAZ phosphorylation and degradation. 2) IGF-1 Axis: Increased IGFBP-1 levels inhibit IGF1, thereby suppressing JAK/STAT signaling. 3) EGF Axis: Decreased EGF/EGFR activity downregulates the RAS/Raf/Erk and AKT/mTOR pathways. 4) Myokine/Cytokine Axis: Elevated IL-8, IL-6, TNF̡, and OSM trigger AMPK, which inhibits the mTORC1 complex. 5) WNT Signaling: Physical activity decreases GSK-3̢ phosphorylation, promoting ̢-catenin degradation. These combined molecular shifts collectively lead to decreased cell proliferation and also influence apoptosis, metastasis, growth rate, angiogenesis, and metabolic processes such as the TCA cycle. The diagram uses standard flow logic (arrows for activation, T-bars for inhibition) to explain the anti-tumorigenic systemic effects of exercise.

This physiological diagram displays nine time-series graphs (A–I) illustrating intracellular calcium ([Ca2+]i) dynamics in adipocytes, measured via Fura-2 fluorescence ratios. The graphs demonstrate the synergistic and potentiation effects of various agonists on calcium signaling. Panels A and B show periodic, high-amplitude [Ca2+]i oscillations induced by the combination of Acetylcholine (ACh) and Norepinephrine (NE). Panel C depicts the inhibition of these oscillations using the M3-cholinergic receptor antagonist p-F-HHSID, resulting in only a single transient spike. Panels D–H illustrate diverse dynamic regimes triggered by ACh and the α1-adrenergic agonist Phenylephrine, including fast oscillations (D), impulse-shaped oscillations (E), relaxation-type oscillations (F), and transitions to new steady states (G, H). Panel I shows impulse-shaped oscillations elicited by the α2-adrenergic agonist UK-14,304 in the presence of ACh. The data illustrate complex nonlinear signaling pathways and the convergence of M3-cholinergic and α-adrenergic receptor activation in adipocyte calcium homeostasis.